G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters affecting bone marrow engraftment

B. J. Bolwell, A. Fishleder, S. W. Andresen, A. E. Lichtin, A. Koo, T. Yanssens, R. Burwell, P. Baucco, Ralph Green

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 μg/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 μg/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 109/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 109/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield. The rapid marrow engraftment resulted in an average total hospital stay of 29 days compared with a historical control of 39 days (p = 0.01). To date, relapse rates of the two study groups have been similar. These data suggest that treatment with G-CSF can result in excellent mobilization of PBPC. Furthermore, the addition of G-CSF primed PBPC plus G-CSF with autologous marrow in ABMT enhances both platelet and neutrophil engraftment rates which ultimately leads to a decreased total hospital stay.

Original languageEnglish (US)
Pages (from-to)609-614
Number of pages6
JournalBone Marrow Transplantation
Volume12
Issue number6
StatePublished - 1993
Externally publishedYes

Fingerprint

Autologous Transplantation
Granulocyte Colony-Stimulating Factor
Bone Marrow Transplantation
Blood Cells
Stem Cells
Bone Marrow
Neutrophils
Blood Platelets
Granulocyte-Macrophage Colony-Stimulating Factor
Length of Stay
Cell Count
Leukapheresis
Blood Volume
Hodgkin Disease
Platelet Count
Non-Hodgkin's Lymphoma
Outpatients
Radiotherapy
Breast Neoplasms
Transplants

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation : Parameters affecting bone marrow engraftment. / Bolwell, B. J.; Fishleder, A.; Andresen, S. W.; Lichtin, A. E.; Koo, A.; Yanssens, T.; Burwell, R.; Baucco, P.; Green, Ralph.

In: Bone Marrow Transplantation, Vol. 12, No. 6, 1993, p. 609-614.

Research output: Contribution to journalArticle

Bolwell, BJ, Fishleder, A, Andresen, SW, Lichtin, AE, Koo, A, Yanssens, T, Burwell, R, Baucco, P & Green, R 1993, 'G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters affecting bone marrow engraftment', Bone Marrow Transplantation, vol. 12, no. 6, pp. 609-614.
Bolwell, B. J. ; Fishleder, A. ; Andresen, S. W. ; Lichtin, A. E. ; Koo, A. ; Yanssens, T. ; Burwell, R. ; Baucco, P. ; Green, Ralph. / G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation : Parameters affecting bone marrow engraftment. In: Bone Marrow Transplantation. 1993 ; Vol. 12, No. 6. pp. 609-614.
@article{cf7fa75e91eb4f29b92e186f6ef0398e,
title = "G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters affecting bone marrow engraftment",
abstract = "G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 μg/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 μg/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 109/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 109/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield. The rapid marrow engraftment resulted in an average total hospital stay of 29 days compared with a historical control of 39 days (p = 0.01). To date, relapse rates of the two study groups have been similar. These data suggest that treatment with G-CSF can result in excellent mobilization of PBPC. Furthermore, the addition of G-CSF primed PBPC plus G-CSF with autologous marrow in ABMT enhances both platelet and neutrophil engraftment rates which ultimately leads to a decreased total hospital stay.",
author = "Bolwell, {B. J.} and A. Fishleder and Andresen, {S. W.} and Lichtin, {A. E.} and A. Koo and T. Yanssens and R. Burwell and P. Baucco and Ralph Green",
year = "1993",
language = "English (US)",
volume = "12",
pages = "609--614",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation

T2 - Parameters affecting bone marrow engraftment

AU - Bolwell, B. J.

AU - Fishleder, A.

AU - Andresen, S. W.

AU - Lichtin, A. E.

AU - Koo, A.

AU - Yanssens, T.

AU - Burwell, R.

AU - Baucco, P.

AU - Green, Ralph

PY - 1993

Y1 - 1993

N2 - G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 μg/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 μg/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 109/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 109/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield. The rapid marrow engraftment resulted in an average total hospital stay of 29 days compared with a historical control of 39 days (p = 0.01). To date, relapse rates of the two study groups have been similar. These data suggest that treatment with G-CSF can result in excellent mobilization of PBPC. Furthermore, the addition of G-CSF primed PBPC plus G-CSF with autologous marrow in ABMT enhances both platelet and neutrophil engraftment rates which ultimately leads to a decreased total hospital stay.

AB - G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 μg/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 μg/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 109/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 109/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield. The rapid marrow engraftment resulted in an average total hospital stay of 29 days compared with a historical control of 39 days (p = 0.01). To date, relapse rates of the two study groups have been similar. These data suggest that treatment with G-CSF can result in excellent mobilization of PBPC. Furthermore, the addition of G-CSF primed PBPC plus G-CSF with autologous marrow in ABMT enhances both platelet and neutrophil engraftment rates which ultimately leads to a decreased total hospital stay.

UR - http://www.scopus.com/inward/record.url?scp=0027716204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027716204&partnerID=8YFLogxK

M3 - Article

C2 - 7511016

AN - SCOPUS:0027716204

VL - 12

SP - 609

EP - 614

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -